Pulmatrix (PULM) Competitors $4.77 +0.30 (+6.62%) As of 08/22/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PULM vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Pulmatrix (NASDAQ:PULM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Do insiders and institutionals believe in ATNFW or PULM? 11.8% of Pulmatrix shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, ATNFW or PULM? 180 Life Sciences has higher earnings, but lower revenue than Pulmatrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/APulmatrix$7.81MN/A-$6.94M-$2.17-2.25 Does the media refer more to ATNFW or PULM? In the previous week, 180 Life Sciences' average media sentiment score of 1.14 beat Pulmatrix's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive Pulmatrix Neutral Is ATNFW or PULM more profitable? 180 Life Sciences has a net margin of 0.00% compared to Pulmatrix's net margin of -122.46%. 180 Life Sciences' return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Pulmatrix -122.46%-97.25%-88.96% Summary180 Life Sciences beats Pulmatrix on 4 of the 7 factors compared between the two stocks. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-2.2521.1431.2226.05Price / SalesN/A350.18435.36102.67Price / CashN/A43.1937.7358.48Price / Book2.008.129.536.61Net Income-$6.94M-$54.72M$3.26B$265.65M7 Day Performance3.82%2.62%2.11%2.02%1 Month Performance-18.77%2.68%2.79%-0.31%1 Year Performance144.50%10.93%30.64%19.06% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.417 of 5 stars$4.89+9.4%N/A+138.5%$0.00$7.81M-2.2520Short Interest ↓Gap UpATNFW180 Life SciencesN/A$0.01-6.6%N/A+2,413.2%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.45+54.4%N/AN/A$0.00$106.21K0.0040ALVOWAlvotechN/A$1.33+4.7%N/A-60.7%$0.00$585.60M0.004News CoverageGap UpARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.06flatN/A-47.7%$0.00N/A0.0015BFRIWBiofronteraN/A$0.14flatN/A+176.6%$0.00$38.00M0.0070BTMDWbioteN/A$0.01+21.0%N/A-97.2%$0.00$199.07M0.00N/AGap UpHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.03-5.1%N/A-90.7%$0.00N/A0.008Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives ARAVIVE Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PULM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access